Evidence map›Paper›PMID 42535721›Full record

ArticleClinical and translational science2026

Human Pharmacokinetic Prediction of Antibody-Drug Conjugates Using Human FcRn Transgenic Mice.

Keitaro Nakagawa, Kenta Haraya

Abstract read
In one paragraph

Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Keitaro NakagawaResearch Division, Chugai Pharmaceutical Co. Ltd, Yokohama, Japan.ORCID 0009-0005-0256-6782
Kenta HarayaResearch Division, Chugai Pharmaceutical Co. Ltd, Yokohama, Japan.ORCID 0000-0002-9142-5607

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-drug conjugates (ADCs) have progressed significantly in recent years, particularly in the oncology field. However, predicting human pharmacokinetics (PK) of ADCs in the early stages of drug development remains challenging. Human neonatal Fc receptor (FcRn) transgenic mice have been established as a reliable pre-clinical PK model for predicting human PK profiles of antibody-based therapeutics. In this study, we investigated the applicability of human FcRn transgenic mice for predicting the human PK of ADCs in a pre-clinical setting. Eight FDA-approved ADCs were administered to human FcRn transgenic mice, and PK parameters were calculated using two-compartment model analysis. The clearance (CL) values of total ADCs in human FcRn transgenic mice showed a strong correlation with human CL (R

Indexed as

Histocompatibility Antigens Class IImmunoconjugatesReceptors, FcAnimalsFemaleHumansMiceMice, TransgenicModels, BiologicalFc receptor, neonatalHistocompatibility Antigens Class IImmunoconjugatesReceptors, Fcallometric scalingantibody‐drug conjugateFcRnpharmacokinetics

Identifiers

PMID42535721
PMCPMC13426018

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.